Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma

20252 citationsJournal Articlegold Open Access

Authors

Jeffrey Hiken · Cofactor Genomics (United States)

Jon Earls · Cofactor Genomics (United States)

Kevin C. Flanagan · Cofactor Genomics (United States)

Rachel L. Wellinghoff · Cofactor Genomics (United States)

Michelle Ponder · Cofactor Genomics (United States)

D. Messina · Cofactor Genomics (United States)

Jarret Glasscock

Abstract

Robust and reliable analytical performance of the OncoPrism-HNSCC assay supports its clinical use, even in the presence of variation typically encountered in the laboratory setting.

Topics & Keywords

RNA modifications and cancer Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Cancer

Volume 25, Issue 1, pp. 21-21

DOI: 10.1186/s12885-024-13362-8

Field-Weighted Citation Impact: 1.71